![Scan_urbina1_0](https://www.hivplusmag.com/media-library/scan-urbina1-0.jpg?id=32675604&width=1200&height=1650)
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Treatment options for people with HIV have increased now that two new classes of drugs--integrase inhibitors and chemokine receptor blockers--have come to market. Medications in both of these new classes are available now, but you need to be careful in how you use them. The first integrase inhibitor, raltegravir (Isentress), works by blocking the 'integration' of HIV into the DNA of our CD4 cells. By doing this, it prevents HIV from taking over our immune cells and making more copies of itself. So far, studies show that this drug is powerful at reducing viral loads and increasing CD4 counts. Additionally, studies indicate that this drug is metabolically 'friendly,' meaning that it does not cause increases in 'bad' cholesterol or blood-sugar levels. This is very important, since people with HIV are at increased risk for heart disease, diabetes, and body changes caused by lipodystrophy. Other good features of this drug are that it can be safely combined with other medications and its potential for drug interactions is very low. Although raltegravir has these promising characteristics, it cannot be used alone. Other antiretrovirals need to be combined with it to make it effective and to prevent the development of resistance against this powerful new medication class. The second new drug to come to market is the entry inhibitor maraviroc (Selzentry), which works by blocking the CCR5, or R5, receptor, one of two on the CD4 cell that HIV uses to make its entry. When blocked by maraviroc, HIV is left hanging until it is destroyed by our immune cells. The other receptor that HIV can use to enter our CD4 cells is the CXCR4, or X4, receptor. Maraviroc will only work if your virus is R5--it cannot block X4 virus. Therefore, before you can use this new medication you will need to have your blood screened to verify which receptor (also called a tropism) your virus uses. A test called the trofile assay requires a simple blood draw and returns results in about two weeks. Your chances of having a virus with only an R5 receptor are greater if you are not heavily treatment-experienced--meaning that you have not been on a lot of anti-HIV meds--and have never had a CD4 count of less than 200 cells. If properly used, maraviroc is potent at lowering viral loads and raising CD4 counts. Unlike raltegravir, this drug's concentration is affected by other drugs, so you and your health care provider will need to review all your other medications to ensure that this drug is properly dosed. And finally, similar to raltegravir, this drug is well-tolerated and is not likely to worsen cholesterol or blood-sugar levels.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
Plus: Featured Video
Latest Stories
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Advocacy in action with AIDSWatch
May 09 2024 12:30 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
The Talk: Finding balance with HIV
May 06 2024 10:51 AM
Justice Dept plans to reschedule marijuana as a lower-risk drug
May 03 2024 2:40 PM
The Talk: Starting your journey with HIV
May 03 2024 2:00 PM
Why is a mother’s mental health so important? A doctor explains
May 01 2024 1:38 PM
Walmart to close all of its health care clinics
April 30 2024 12:30 PM
Vampire facial spa infected several women with HIV
April 29 2024 7:26 PM